NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer
NervGen Pharma appointed Keith Vendola, MD, MBA, as Chief Financial Officer, effective immediately, adding over two decades of experience in biopharma finance and strategy. The company is accelerating clinical development of NVG-291 toward the RESTORE registrational study in chronic tetraplegia, where Dr. Vendola's capital markets expertise will be instrumental.
Key figures
- Drug Name
- NVG-291
- Phase Of Trial
- Phase 1b/2a
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.